The activity of G protein-coupled receptors (GPCRs) can be modulated by a diverse spectrum of drugs ranging from full agonists to partial agonists, antagonists, and inverse agonists. The vast majority of these ligands compete with native ligands for binding to orthosteric binding sites. Allosteric ligands have also been described for a number of GPCRs. However, little is known about the mechanism by which these ligands modulate the affinity of receptors for orthosteric ligands. We have previously reported that Zn(II) acts as a positive allosteric modulator of the ␤ 2 -adrenergic receptor (␤ 2 AR). To identify the Zn 2؉ binding site responsible for the enhancement of agonist affinity in the ␤ 2 AR, we mutated histidines located in hydrophilic sequences bridging the seven transmembrane domains. Mutation of His-269 abolished the effect of Zn 2؉ on agonist affinity. Mutations of other histidines had no effect on agonist affinity. Further mutagenesis of residues adjacent to His-269 demonstrated that Cys-265 and Glu-225 are also required to achieve the full allosteric effect of Zn 2؉ on agonist binding. Our results suggest that bridging of the cytoplasmic extensions of TM5 and TM6 by Zn 2؉ facilitates agonist binding. These results are in agreement with recent biophysical studies demonstrating that agonist binding leads to movement of TM6 relative to TM5.
G protein-coupled receptors (GPCR) 1 respond to a wide range of structurally diverse natural and synthetic ligands. The majority of these ligands are classified as orthosteres. They compete for binding with the natural ligand, and their binding site is predicted to overlap with that of the natural ligand. Allosteric modulation of ligand binding has been observed for several GPCRs. Allosteric modulators include physiologically relevant ions as well as small organic molecules. A large number of compounds allosterically increase binding affinity for muscarinic receptor antagonists. Allosteric regulation can be demonstrated in all five subtypes of muscarinic receptors, but the m2 receptor appears to be the most sensitive (1) . Although most allosteric modulators for the muscarinic receptors affect antagonist binding, allosteric modulation of agonist binding has also been described (2) .
In addition to the muscarinic receptor, allosteric compounds have been identified for the A1 adenosine receptor. The 2-amino-3-benzoylthiophene, PD 81,723, has been shown to enhance agonist binding and G protein coupling in a Mg 2ϩ -dependent manner (3, 4) .
The function of several G i -coupled receptors has been shown to be modulated by amilioride analogs and by Na ϩ . This effect has been particularly well characterized for the ␣2 adrenergic receptor (5-7) and for the dopamine D2 (8) and D4 subtypes (9) . Na ϩ both uncouples the receptor from G i and reduces agonist affinity. A conserved Asp residue within the cytoplasmic side of TM2 is responsible for the Na ϩ -sensitive binding of the ␣2A receptor (6) and the D4 dopamine receptor (9) . This Na ϩ sensitivity may be physiologically relevant, as relatively high local concentrations of Na ϩ ions may accumulate at the cytoplasmic side of the receptor after membrane depolarization.
Recently the function of the calcium receptor has been shown to be positively modulated by certain L-amino acids (10, 11) . This finding may be physiologically relevant as nutrient and Ca 2ϩ homeostasis may be coordinately regulated.
We recently reported that Zn 2ϩ has complex effects on the functional properties of the ␤ 2 AR (12). Zn 2ϩ binding to a high affinity site (IC 50 ϳ5 M) enhances agonist affinity, whereas Zn 2ϩ binding to one or more low affinity sites (IC 50 Ͼ500 M) inhibits antagonist binding and yet slows antagonist dissociation. To identify the Zn 2ϩ binding site responsible for the positive allosteric effect of Zn 2ϩ on agonist affinity, we mutated seven histidines located in intracellular and extracellular hydrophilic sequences connecting transmembrane (TM) domains. Mutation of His-269 dramatically reduced the effect of Zn 2ϩ on agonist affinity. Mutations of other histidines had no effect. Further mutagenesis of residues predicted to be adjacent to His-269 in the three-dimensional structure of the ␤ 2 AR revealed that Cys-265 and Glu-225 are also required to achieve the full allosteric effect of Zn 2ϩ on agonist binding. Our results suggest that bridging of the cytoplasmic extensions of TM5 and TM6 by Zn 2ϩ facilitates agonist binding. These results are in agreement with recent biophysical studies demonstrating that agonist binding leads to movement of TM6 relative to TM5.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis-The cDNA sequence encoding the human ␤ 2 AR, epitope-tagged at the amino terminus with a cleavable influenzahemagglutinin signal sequence followed by the FLAG epitope (IBI, New Haven, CT) and tagged with six histidines at the carboxyl terminus, was used as a template for mutagenesis (13) . This cDNA was subcloned in baculovirus expression vector pACMP2 at BamHI/EcoRI site. Mutations were generated by the polymerase chain reaction-mediated mutagenesis using Pfu polymerase (Stratagene). The polymerase-generated DNA fragments were subcloned into pACMP2 plasmid, and the * This work was supported in part by National Institute of Health Grant 5-RO1-NS28471 and the Mathers Charitable Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Expression of the Receptors in SF9 Insect Cells-SF-h␤ 2 -6H and the mutant constructs in the baculovirus expression vector pACMP2 were co-transfected with linearized Sapphire TM Baculovirus DNA into SF9 insect cells using the Insectin Plus transfection kit (Invitrogen). The resulting viruses were harvested 4 -5 days and amplified for another 4 -5 days to obtain a high titer virus. SF9 insect cells were grown in suspension culture in SF-900 II medium (Invitrogen) containing 5% fetal calf serum (Gemini, Calabasas, CA) and 0.1 mg/ml gentamicin (Invitrogen). For membrane preparation the cells were grown in 100-ml cultures. Cells were infected with a 1:100 dilution of a high titer virus stock at a density of 3.5-5.5 ϫ 10 6 cells/ml and harvested after 48 h by centrifugation for 10 min at 5000 ϫ g. The resulting cell pellets were kept at Ϫ80°C until further use.
Membrane Preparation-All of the membrane preparation steps were done at 4°C as described elsewhere (12) . Cells were harvested and washed once with phosphate-buffer saline, recentrifuged, and then resuspended in lysis buffer (10 mM Tris-HCl, pH 7.5, with 1 mM EDTA) containing protease inhibitors (leupeptin and benzamidine at a final concentration of 10 g/ml) and lysed using 25 strokes of a Dounce homogenizer. Nuclei and unbroken cells were removed by centrifugation (5 min at 500g). The supernatant was removed and centrifuged at 40,000 ϫ g for 30 min. The resulting pellet was resuspended in 20 ml of 10 mM Tris-HCl, pH 7.5, buffer alone containing protease inhibitors and recentrifuged. Membranes were resuspended at 0.5-1.5 mg/ml in binding buffer (75 mM Tris-HCl, pH 7.5) and stored at Ϫ80°C until use.
Binding Assays-All of the binding assays were done on SF9 membranes expressing either the WT␤ 2 AR or mutant receptors. The saturation binding assays were done by incubating the membranes (20 -50 g) with 10 different concentrations of the antagonist [ 3 H]DHA between 100 pM and 20 nM with or without 1 mM Zn(II). Competition assays were done by incubating the membranes with different concentrations of agonist isoproterenol (10 Ϫ9 to 10 Ϫ3 M) with or without 20 M Zn(II). Zn 2ϩ modified competition assays were also done similar to competition assays expect that membranes were incubated with different concentrations of Zn(II) (0.3-300 M) in the presence or absence of 100 nM isoproterenol. All of the assays were performed for 1 h at room temperature with shaking at 230 rpm. cAMP Accumulation-The production of cAMP was determined by adenylyl cyclase activation FlashPlate assay (PerkinElmer Life Sciences), in which 96-well plates are coated with solid scintillant to which anti-cyclic cAMP antibody has been bound. Briefly, HEK293 cells expressing stable human ␤ 2 AR and mutants were detached, washed four times in 1ϫ phosphate-buffered saline without Ca 2ϩ /Mg 2ϩ , and then resuspended to a density of ϳ2 ϫ 10 6 cells/ml in stimulation buffer (1ϫ phosphate-buffered saline without calcium/magnesium, with 700 M 3-isobutyl-1-methylxanthine, 0.1% protease-free bovine serum albumin, and 0.09% chloroacetamide) from PerkinElmer Life Sciences. Ligands (25 l each) were diluted in Milli-Q water with various concentrations and dispensed to the FlashPlate. Resuspended whole cells (50 l) were added to the ligand-loaded plate and stimulated at 37°C for 10 min before lysing cells with 100 l of Detection Buffer (Invitrogen) containing [
125 I]cAMP, permeabilizer, and 0.09% sodium azide as provided by the manufacturer. After 2 h of incubation at room temperature, radioactivity was counted. To determine the concentrations of cAMP in the sample, cAMP standards were run in the same plate and expressed as pmol/well. (Fig. 1A) . The maximal effect of Zn 2ϩ on isoproterenol affinity occurs at ϳ20 M with an IC 50 of 3.0 M (12). These effects of (Fig. 1B) . In contrast, the affinity of the ␤ 2 AR for isoproterenol is enhanced in the presence of 20 M Zn 2ϩ (Fig. 1C) .
Identification of the Allosteric Binding Site for Zn
2ϩ -Histidines are often involved in the formation of Zn 2ϩ binding sites in proteins (14, 15) . We hypothesized that the Zn 2ϩ binding site responsible for the positive allosteric effect on agonist binding to the ␤ 2 AR would be located in extracellular loops. However, mutations of histidines 93, 172, 178, and 296 (Fig. 2 ) had no effect on the positive allosteric effect of Zn 2ϩ (data not shown). We therefore examined the role of cytoplasmic histidines (His-241, His-256, and His-269) (Fig. 2) . Of these, only H269A exhibited a reduced response to Zn 2ϩ . The effect of Zn 2ϩ on both agonist and antagonist affinity is nearly abolished in H269A ( Fig. 3 ; Tables I and II High affinity Zn 2ϩ binding requires coordination by at least two amino acids. In addition to histidine, cysteine, aspartate, and glutamate can contribute to the formation of a Zn 2ϩ binding site (16, 17) . We therefore used a three-dimensional model based on rhodopsin (18) to identify cysteines as well as acidic residues in proximity to His-269. This analysis identified the closest candidates as Cys-265 on the cytoplasmic end of TM6 and Glu-225 on the cytoplasmic end of TM5. Mutation of Glu-225 and Cys-265 to alanine had no significant effect on either agonist or antagonist affinity in the absence of Zn 2ϩ (Tables I  and II) . However, both mutant receptors had altered agonist and antagonist responses to Zn 2ϩ . For both mutants there was a smaller decrease in antagonist affinity in the presence of 1 mM Zn 2ϩ (Table I ) and a smaller increase in agonist affinity in the presence of 20 M Zn 2ϩ (Table II) . The effect of Zn 2ϩ on agonist affinity is almost abolished for the double mutant E225A/H269A and completely abolished when C265A is combined with H269A (Tables I and II, and Fig. 4) .
Zn
2ϩ Augmentation of ISO-stimulated cAMP Accumulation-We previously reported that low concentrations of Zn 2ϩ enhance cAMP accumulation by submaximal concentrations of isoproterenol in intact cells (12) . To determine whether the Zn 2ϩ site formed by His-269, Cys-265, and Glu-225 is also responsible for the effect of Zn 2ϩ on cAMP accumulation, we generated stable cell lines expressing the wild-type ␤ 2 AR as well as H269A, C265A, C265A/H2269A, and E225A/H269A. not responsible for the effect of Zn 2ϩ on cAMP accumulation in intact cells. DISCUSSION Allosteric ligands have been identified for only a small number of GPCRs including the M2 muscarinic receptor (19) , the A1 adenosine receptor (3) , and the Ca 2ϩ -sensitive receptor (11) . Binding of the well characterized muscarinic allosteric ligand gallamine has been mapped to extracellular loops 2 and 3 (20, 21) . It has been proposed that, when bound to gallamine, extracellular loops 2 and 3 may form a plug over the binding pocket, thereby slowing the dissociation rate (22) .
Another well characterized allosteric modulator of GPCR function is ionized sodium. Sodium ions act as negative allosteric regulators for a number of Gi-coupled receptors including the ␣ 2A adrenergic receptor and the D2 and D4 dopamine receptor. In contrast to the extracellular location of the allosteric binding site for gallamine in muscarinic receptors, sodium sensitivity is mediated at the cytoplasmic surface of the receptor. A highly conserved Asp at the cytoplasmic end of TM2 has been shown to be critical for this effect of sodium (6, 9) .
Our mutagenesis studies localize the binding site responsible for the positive allosteric effect of Zn 2ϩ on agonist affinity to the third intracellular loop. This Zn 2ϩ binding site consists of Cys-265 and His-269 on the cytoplasmic extension of TM6 and Glu-225 on the cytoplasmic extension of TM5. This location is of particular interest because recent biophysical studies from our laboratory demonstrate that agonist binding is associated with a movement of Cys-265 on TM6 relative to TM5 (23) . These studies were performed on purified ␤ 2 AR labeled at Cys-265 with fluorescein. Moreover, cysteine cross-linking studies on the M3 muscarinic receptor provide evidence for agonist-in- duced movement of the cytoplasmic end of TM5 relative to TM6 (24) . Thus, Zn 2ϩ may form a bridge between TM5 and TM6. This bridge is likely to alter the position of TM5 relative to TM6. On the basis of these observations, we speculate that Zn 2ϩ binding approximates or stabilizes the conformational changes induced by agonists. It is of interest that this Zn 2ϩ binding site is not responsible for the ability of Zn 2ϩ to augment cAMP accumulation by submaximal concentrations of isoproterenol (Fig. 5) or for the effect of Zn 2ϩ on antagonist dissociation (data not shown).
In conclusion, we have identified the Zn 2ϩ binding site responsible for the positive effect of Zn 2ϩ ions on agonist binding to the ␤ 2 AR. Our results suggest that Zn 2ϩ stabilizes an orientation of TM6 relative to TM5 that favors agonist binding and inhibits antagonist binding. These results provide further evidence for the role of TM5 and TM6 in agonist-induced conformational changes.
